phenylalanine ammonia lyase/erythema

鏈接已保存到剪貼板

文章臨床試驗專利權

選擇排序類型

3 結果

Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study.

只有註冊用戶可以翻譯文章

登陸註冊

BACKGROUND Deficiency of phenylalanine hydroxylase causes phenylketonuria (PKU) with elevated phenylalanine (Phe) levels and associated neuropsychiatric and neurocognitive symptoms. Pegvaliase (PEGylated phenylalanine ammonia lyase) is an investigational agent to lower plasma Phe in adults with PKU.

Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).

只有註冊用戶可以翻譯文章

登陸註冊

BACKGROUND Phenylketonuria (PKU) is caused by phenylalanine hydroxylase (PAH) deficiency that results in phenylalanine (Phe) accumulation. Pegvaliase, PEGylated recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL), converts Phe to trans-cinnamic acid and ammonia, and is a potential

Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-up

只有註冊用戶可以翻譯文章

登陸註冊

Background: Phenylketonuria (PKU) is characterized by a deficiency in phenylalanine hydroxylase (PAH) that may lead to elevated blood phenylalanine (Phe) and significant neurocognitive and neuropsychological comorbidities. Pegvaliase

加入我們的臉書專頁

Herbal & Natural Medicine

科學支持的最完整的草藥數據庫

支持55種語言
科學支持的草藥療法
通過圖像識別草藥
交互式GPS地圖-在位置標記草藥（即將推出）
閱讀與您的搜索相關的科學出版物
通過藥效搜索藥草
組織您的興趣並及時了解新聞研究，臨床試驗和專利

輸入症狀或疾病，並閱讀可能有用的草藥，輸入草藥並查看其所針對的疾病和症狀。
*所有信息均基於已發表的科學研究